Condition: HIV/AIDS and Infections · Sponsor: ANRS, Emerging Infectious Diseases
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART initiation.
This description comes directly from the study's public registry record.
Mathilde Ghislain, MSc · +331 45 59 52 29 · mathilde.ghislain@inserm.fr
Nicolas Leturque, MSc · +331 45 59 51 93 · nicolas.leturque@inserm.fr
Always discuss trial participation with your own doctor first.
| Hôpial Avicenne - SMIT | Bobigny, France | Recruiting |
| Hôpital Antoine Béclère | Clamart, France | Recruiting |
| Hôpital Beaujon - Service de médecine interne | Clichy, France | Recruiting |
| CHI Créteil - HdJ | Créteil, France | Recruiting |
| Hôpital Raymond Poincaré - SMIT | Garches, France | Recruiting |
| Hôpital Bicêtre - HdJ - Médecine interne | Le Kremlin-Bicêtre, France | Recruiting |
| Hôpital Hôtel - Dieu | Paris, France | Recruiting |
| Hôpital Hôtel Dieu - Service d'immunologie clinique | Paris, France | Not Yet Recruiting |
| Hôpital Pitié-Salpêtrière - SMIT | Paris, France | Recruiting |
| Hôpital Lariboisière - Service de médecine interne A | Paris, France | Recruiting |
| Hôpital Saint- Louis - SMIT | Paris, France | Recruiting |
| Hôpital Saint-Antoine - SMIT | Paris, France | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05300035